CD25 Monoclonal Antibody (Basiliximab) Used in High Risk Kidney Recipient (Single Center Experience).
- Author:
Hyeong Tae KIM
1
;
Won Hyun CHO
;
Hyun Jin LEE
;
Eun A HWANG
;
Seung Yup HAN
;
Sung Bae PARK
;
Hyun Chul KIM
Author Information
1. Department of Surgery, Keimyung University School of Medicine, Daegu, Korea. wh51cho@dsmc.or.kr
- Publication Type:Original Article
- Keywords:
CD25 monoclonal antibody;
Basiliximab;
Kidney;
Transplantation;
High risk recipient
- MeSH:
Cadaver;
Calcineurin;
Creatinine;
Cyclosporine;
Graft Survival;
Immunosuppression;
Incidence;
Kidney Transplantation;
Kidney*;
Muromonab-CD3;
Risk Factors;
Tacrolimus;
Transplantation
- From:The Journal of the Korean Society for Transplantation
2007;21(1):98-104
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: CD25 monoclonal antibody (basiliximab, BA) has been reported an excellent effect on induction immunosuppression than ALG, ATG, OKT3 in renal transplantation. Since we can use BA only in the group of high risk kidney recipient, we want to evaluate the effect of BA treated group by comparing with conventional 3 drugs combination group (calcineurin inhibitor/cyclosporine or tacrolimus, mycophenolate mofetil and prednisolon). METHODS: Total 103 recipients were treated by BA and conventional 3 drugs from March 2000 through February 2006, and these cases were compared with 122 recipients without BA. Government guidelines for using BA were in cadaveric transplantation, more than 4 HLA mismatching, zero DR antigen matching, retransplantation and more than 80% positive PRA. The episode of acute rejection (AR), steriod resistant acute rejection, change of serum creatinine, maintaining dosage of calcineurin inhibitor (CNI) and other side effects were compared between groups. RESULTS: The rate of AR within 12 months after transplantation was 11.7% in BA group while 9.0% in control group (P=0.451). The steroid resistant acute rejection was 16.6% in BA group and 27.3% in control group (P=0.119). Rejection free graft survival adjusted various clinical risk factors by Cox-regression test were no significance between groups. Serum creatinine level at one year after transplantation was 1.61+/-.1 and 1.46+/-.7 mg/dL in BA and control group, and recipients number whose SCr over 1.5 mg/dL were 39.0% and 32.7% (P=0.326). Cyclosporin dosage at one year in BA and control group were 4.21 and 3.62 mg/kg (P=0.202) and 0.11 and 0.17 mg/kg in tacrolimus group (P=0.291). Incidence of PTDM and viral infection were all no difference statistically between groups. CONCLUSION: In conclusion, BA induction immunosuppression with CNI, mycophenolate mofetil and prednisolon used in high risk kidney recipient effectively control the acute rejection and steroid resistant acute rejection for one year at least the same as control group. But since there was no more beneficial effect in BA added to Tac group than conventional Tac based immunosuppression, this 4 drug combination is better avoided if possible.
